Esperion Shares Flat at $3.16 as Archimed Bid Nears Endgame
Esperion Therapeutics shares held at $3.13 late Wednesday, just below Archimed’s $3.16-a-share cash offer, as investors assessed closing and milestone risks in the $1.1 billion take-private deal. The stock saw volume above 7 million shares. The merger includes a contingent value right tied to future drug sales. Esperion’s first-quarter revenue rose to $80.1 million, with a net loss narrowing to $25.2 million.
